Moderate Evidence
Research Overview
Thymalin Research for Post-Viral Immune Dysfunction
An evidence-based overview of research examining Thymalin in the context of post-viral immune dysfunction. This page synthesizes findings from peer-reviewed literature.
Research Summary
A 2023 mechanistic study from the Khavinson laboratory examined Thymalin and its active EW/KE dipeptides in the context of COVID-19, showing in human peripheral blood mononuclear cells that they suppress the cytokine-storm cytokines IL-1B, IL-6 and TNF-a by 1.4-6.0 fold. This is laboratory/in-vitro evidence rather than a controlled clinical trial.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.